Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 10, 2021 / 12:50PM GMT
Release Date Price: $84.11 (+1.37%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning, everyone. Thanks for joining us. I'm Salveen Richter, Biotechnology Analyst at Goldman Sachs, and we're really pleased to have Blueprint with us. From the company, we have Jeff Albers, CEO; and Fouad Namouni, President of R&D.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

With that, to start, Jeff, maybe you could talk about your ex U.S. footprint in the recent collaborations with Roche, what is strategy for other assets and partnerships and leveraging the existing infrastructure?

Jeffrey W. Albers
Blueprint Medicines Corporation - Chairman of the Board, CEO & President

Sure. First of, Salveen, thanks for including us. And on behalf of the employees of Blueprint Medicines, I want to thank you and the Goldman Sachs team.

Obviously, we will be making forward-looking statements, so disclaim any obligation to update those and would refer people to our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot